Weekly Analysts’ Ratings Changes for Rezolute (RZLT)

Several brokerages have updated their recommendations and price targets on shares of Rezolute (NASDAQ: RZLT) in the last few weeks:

• 10/6/2026 – Rezolute had its price target raised by Lake Street Capital from $9.00 to $12.00. They now have a “buy” rating on the stock.
• 10/6/2026 – Rezolute had its “outperform” rating reaffirmed by Citigroup Inc..
• 10/6/2026 – Rezolute had its price target raised by Citizens Jmp from $11.00 to $15.00. They now have a “market outperform” rating on the stock.
• 10/5/2026 – Rezolute was upgraded by Cantor Fitzgerald from “neutral” to “overweight”.
• 9/30/2026 – Rezolute is now covered by Lake Street Capital. They set a “buy” rating and a $9.00 price target on the stock.
• 9/29/2026 – Rezolute was upgraded by Craig Hallum from “hold” to “buy”. They now have a $7.00 price target on the stock, up from $4.00.
• 9/25/2026 – Rezolute was upgraded by HSBC Holdings plc to “buy”.
• 9/25/2026 – Rezolute had its “market outperform” rating reaffirmed by Citigroup Inc..
• 9/25/2026 – Rezolute had its price target raised by HC Wainwright from $5.00 to $10.00. They now have a “buy” rating on the stock.

Rezolute, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. The company’s research is centered on conditions involving abnormal insulin signaling and glucose regulation, including rare disorders and complications associated with diabetes.

Rezolute’s lead investigational product is RZ358, a human monoclonal antibody designed to reduce the effects of excessive insulin activity. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin and causes potentially dangerous episodes of low blood sugar.